SC
AMPH icon

Stephens Consulting’s Amphastar Pharmaceuticals AMPH Stock Holding History

Stephens Consulting’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$435 – 1229
2025
Q1 		$435 Buy
+15
New +$479 ﹤0.01% 964

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stephens Consulting's AMPH Position: Q2 2025 in Review

Stephens Consulting sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 15 shares — an estimated $435 sold.

Stephens Consulting first reported a position in AMPH in Q1 2025 and held it in 1 quarter. The position peaked at $435 in Q1 2025. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Stephens Consulting reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $435.
  • Stephens Consulting first reported a position in Amphastar Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Amphastar Pharmaceuticals position peaked at $435 in Q1 2025.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.